ClinicalTrials.gg
RecruitingNCT07946146Updated Nov 18, 2026

A Single-Center, Prospective Clinical Cohort Study on Perioperative Management, Exposure, Multiorgan Outcomes, and Functional Recovery in Liver Transplantation

An observational study in Liver Transplantation (LT), Perioperative Care and Prospective Studies, sponsored by Beijing Tsinghua Chang Gung Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 158 studies in Postoperative Complications with a site in China — 46 open to participants now, 53 under way, none of them phase 3. Postoperative Complications · China.

Planned enrollment
33rd of 63
450 · median 472
Started
2026
with 16 others
Observational
63 of 158
16 open now
Primary completion
2031-10
later than 52 of 52 live
Registered
158th of 158
by date
Lead sponsor
3 of 158
Beijing Tsinghua Chang Gung Hospital

Among the 158 studies in Postoperative Complications with a site in China, this one is the 33rd largest by planned enrollment of the 63 observational ones that give a count, is one of 17 that started in 2026, is one of 63 observational ones, reaches primary completion later than 52 of the 52 other live ones, and was the 158th registered.

Postoperative Complications

1,338 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.

Browse Postoperative Complications studies →

Open to participants now

46 of the 158 studies in Postoperative Complications with a site in China are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 201 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 32 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Postoperative Complications with a site in China, or all of them as a file.
02

Study summary

The objective of this observational study (a single-center, prospective, consecutively enrolled clinical cohort) is to establish a cohort of adult liver transplant recipients to correlate, within the same population, the recipients' preoperative status with graft condition, perioperative medical and therapeutic exposures, and dynamic physiological changes, as well as multiorgan outcomes and functional recovery; to identify factors associated with organ injury and difficulties in recovery; and to provide a basis for subsequent clinical validation and intervention studies. The study population consists of adult recipients aged ≥18 years who are scheduled to undergo their first single-liver transplant at this center; continuous enrollment is planned for 5 years, with a target of 450 participants, each followed for 12 months. Recipients undergoing repeat liver transplantation or combined organ transplantation will be included only in a separate expanded registry and analysis.

The primary research questions it aims to address are:

What is the incidence rate and 95% confidence interval of the patient-level composite outcome-defined as all-cause mortality or at least one of the predefined major organ complications (early graft dysfunction/graft failure, new-onset or worsening moderate-to-severe acute kidney injury, new-onset delirium or confirmed acute neurological event, major cardiovascular event, or major pulmonary complication)-within 30 days after the start of the transplant procedure? After accounting for preoperative disease severity, organ function, and graft condition, how are perioperative clinical exposures and physiological changes-such as circulatory, respiratory, temperature, and EEG parameters-associated with multiorgan outcomes and functional recovery at 12 months? Can prespecified dynamic physiological data provide additional information regarding risk or recovery beyond routine clinical data?

This study has no control group; no treatment will be assigned; routine monitoring, testing, or rehabilitation arrangements will not be altered; and no additional blood draws or tissue samples will be collected. Participants will:

Undergo preoperative baseline data collection and assessments of cognition, frailty, functional status, and quality of recovery; some participants will complete the sleep and mood extension modules (PSQI, HADS).

During the perioperative period, participants will allow the research team to record clinically generated treatment exposures and multimodal monitoring data, including circulatory, respiratory, temperature, and EEG parameters.

Participants will complete relevant follow-up visits and functional assessments on postoperative days 7, 30, and 90, as well as at 6 and 12 months, including the QoR-15, DAH-30/90, and assessments of cognition, frailty, functional status, and quality of life.

Follow-up should preferably be conducted in conjunction with routine follow-up visits; when necessary, survival, hospitalization, and living conditions may be verified via approved telephone contact. Additional clinical testing using residual serum and tissue samples is optional; refusal to provide these samples will not affect enrollment in the study.

03

Conditions studied

  • Liver Transplantation (LT)
  • Perioperative Care
  • Prospective Studies
  • Cohort Studies
  • Postoperative Complications
  • Multiple Organ Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a single-center study, and the study population is sourced from Beijing Tsinghua Changgung Hospital. Adult recipients (aged ≥18 years) scheduled to undergo primary single liver transplantation at this center are consecutively screened during waitlist registration, inpatient preoperative evaluation, or pre-transplant preparation. With an estimated 100 adult liver transplant surgeries performed annually at this center, approximately 450 recipients are planned to be enrolled consecutively over a 5-year period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Scheduled to undergo primary single liver transplantation at this center.
  3. The participant or legally authorized representative has completed the ethically approved process.

(Note: Patients undergoing emergency transplantation, preoperative hepatic encephalopathy, intensive care, mechanical ventilation, and renal replacement therapy are eligible. Donor type and disease severity will be retained as stratification information.)

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years.
  2. History of previous liver transplantation.
  3. This surgery is a combined organ transplantation.
  4. Refusal to participate.
  5. Unable to complete valid authorization under the procedure approved for this study.

(Note: Patients undergoing re-transplantation and combined organ transplantation may enter a separate extended registry within the same ethical framework, but will not be mixed into the primary analysis cohort of primary single liver transplantation and its sample size denominator.)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherNo Intervention: Observational Cohort

    No intervention

06

What researchers measure

Primary outcomes

  1. Number of participants with all-cause mortality or at least one major organ complication within 30 days after the start of transplant surgery, assessed according to preset clinical criteria (e.g., Olthoff definition, KDIGO criteria).

    Time frame: From the start of surgery to 30 days postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cywinski JB, Li Y, Liu X, Khanna S, Irefin S, Mousa A, Maheshwari K. Intraoperative hypotension during liver transplantation and postoperative outcomes: Retrospective cohort study. J Clin Anesth. 2024 Sep;96:111486. doi: 10.1016/j.jclinane.2024.111486. Epub 2024 May 9. PubMed 38728933 ↗
  • Puchades L, Herreras J, Cebria I Iranzo MA, Reyes E, Crespo G, Rodriguez-Peralvarez M, Cortes L, Serrano T, Fernandez-Yunquera A, Montalva E, Berenguer M. Frailty Changes After Liver Transplantation. Results From a Spanish Multicenter Prospective Cohort Study. Transplant Direct. 2024 Mar 22;10(4):e1599. doi: 10.1097/TXD.0000000000001599. eCollection 2024 Apr. PubMed 38529356 ↗
  • Pollok JM, Tinguely P, Berenguer M, Niemann CU, Raptis DA, Spiro M; ERAS4OLT.org collaborative. Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):81-94. doi: 10.1016/S2468-1253(22)00268-0. PubMed 36495912 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2031, 60 months after the start.

Of 277 non-industry observational studies under Postoperative Complications, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 60 months is above that.

Counting every sponsor, half of 282 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Oct 22, 2026
Primary completionEst.
Oct 22, 2031
CompletionEst.
Oct 22, 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946146
Responsible party
Yi Duan (Associate Chief Physician, Beijing Tsinghua Chang Gung Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Oct 22, 2026
Primary completion
Oct 22, 2031 (estimated)
Completion
Oct 22, 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

Yi Duan, Master's Degree
Contact
Dya01610@btch.edu.cn
+86 13810385311

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion